

# Elemental Nutrition in Gastrointestinal symptom management during pelvic radiotherapy (enigma)

<b>Submission date</b> 30/09/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 30/09/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 10/09/2012	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Jervoise Andreyev

**Contact details**  
Medicine Section  
Royal Marsden NHS Trust  
Downs Road  
Sutton, Surrey  
United Kingdom  
SM2 5PT  
+44 (0)20 8643 8901

## Additional identifiers

**Protocol serial number**  
N0258152650

## Study information

**Scientific Title**

**Acronym**

ENiGMa

**Study objectives**

To identify in patients having pelvic radiotherapy if elemental diet given for 3 weeks can reduce bowel symptoms and change other indicators of these symptoms.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Primary study design**

Interventional

**Study design**

Randomised open label controlled parallel group trial

**Study type(s)**

Not Specified

**Health condition(s) or problem(s) studied**

Pelvic cancers

**Interventions**

Randomised test intervention versus no intervention controls, non-blinded Phase III

**Intervention Type**

Other

**Phase**

Phase III

**Primary outcome(s)**

To assess bowel toxicity using IBDQ and to assess whether there are differences in the score in patients in their intervention arm and the control.

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

31/07/2006

**Eligibility****Key inclusion criteria**

102 RMH patients, with a diagnosis of gynaecological or urological malignancy. Will be undergoing a course of radical or adjuvant pelvic radiotherapy to a curative dose (including patients undergoing concomitant chemotherapy).

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

1. Patients with condition precluding oral nutrition
2. Patients undergoing conformal radiotherapy or intra-cavity brachytherapy
3. Patients with clotting disorders

**Date of first enrolment**

25/11/2004

**Date of final enrolment**

31/07/2006

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre****Medicine Section**

Sutton, Surrey  
United Kingdom  
SM2 5PT

**Sponsor information****Organisation**

Department of Health

**Funder(s)**

**Funder type**  
Government

**Funder Name**  
The Royal Marsden NHS Foundation Trust (UK)

**Funder Name**  
NHS R&D Support Funding

## Results and Publications

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**  
Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/06/2008		Yes	No